Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Common Equity (2023 - 2026)

Beta Bionics' Common Equity history spans 4 years, with the latest figure at $271.2 million for Q1 2026.

  • On a quarterly basis, Common Equity fell 13.55% to $271.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $271.2 million, a 13.55% decrease, with the full-year FY2025 number at $287.6 million, up 217.22% from a year prior.
  • Common Equity hit $271.2 million in Q1 2026 for Beta Bionics, down from $287.6 million in the prior quarter.
  • Over the last five years, Common Equity for BBNX hit a ceiling of $313.8 million in Q1 2025 and a floor of -$245.4 million in Q4 2024.
  • Historically, Common Equity has averaged $35.6 million across 4 years, with a median of $34.1 million in 2023.
  • Biggest five-year swings in Common Equity: fell 20.8% in 2024 and later soared 246.39% in 2025.
  • Tracing BBNX's Common Equity over 4 years: stood at -$203.1 million in 2023, then dropped by 20.8% to -$245.4 million in 2024, then soared by 217.22% to $287.6 million in 2025, then decreased by 5.69% to $271.2 million in 2026.
  • Business Quant data shows Common Equity for BBNX at $271.2 million in Q1 2026, $287.6 million in Q4 2025, and $294.8 million in Q3 2025.